Cell Therapy and Gene Therapy Markets, 2021-2031

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

• Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2021-2031

 

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

Cell Therapy

• Table 2-1: Adult vs. Embryonic Stem Cells

Gene Therapy

• Table 2-2: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

• Table 2-3: Selected Examples of Viruses in Gene Therapy
• Figure 2-1: Viral Vector Use in Commercialized Cell and Gene Therapies

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

• Table 2-4: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

• Table 2-5: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
• Figure 2-2: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
• Table 2-6: Selected Recent Viral Vector Company Expansion

Cost

Reimbursement

Logistics

Mergers and Acquisitions

• Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Partnerships, Agreements and Collaborations

• Table 2-8: Selected  Company Partnerships, Agreements and Collaborations in the Cell and Gene Therapy Market

Financing and Funding Deals

• Table 2-9: Recent Cell and Gene Therapy Recent Financing Deals

Regulatory Developments

• Figure 2-3: FDA Cell & Gene Therapy Percent of Projects with Orphan Drug and/or Fast Track Status

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

• Table 2-10: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country

Individualized Gene Therapy Approval Process

Development and Pipeline Overview

Development Progress

• Figure 2-4: Global Cell and Gene Therapy Development Progress (phase I through phase III), as of January 2022
• Figure 2-5: Global Cell and Gene Therapy Development Progress by Phase, as of January 2022

Development by Condition/Disorder

• Figure 2-6: Global Development of Cell and Gene Therapies by Target

Global Participation in Cell and Gene Therapy Development

• Figure 2-7: Global Development Activity of Cell and Gene Therapies by Country, as of January 2022

Phase III Development

• Table 2-11: Phase III Development ¾ Cell and Gene Therapies, Select Projects
• Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)

End User

Hospitals

Research Institutes

Wound Care Centers

Cancer Centers

 

Chapter 3: Cell and Gene Therapy Markets in Dermatology

Overview

• Table 3-1: Wound Prevalence by Type

Market Outlook

• Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2021-2031 ($ millions)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

• Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
• Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

• Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
• Table 3-4: Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

• Table 3-5: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

• Table 3-6: Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

• Table 3-7: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
• Figure 3-3: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Dermatology Cell and Gene Therapy Market by Indication

• Table 3-8: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)

Regional Market Summary

• Figure 3-4: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2021
• Table 3-9: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
• Figure: 3-5: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

• Table 3-10: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

• Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2021-2031, ($ millions)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

Cord Blood Products

• Table 4-1:  Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
• Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

• Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
• Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

• Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

• Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

• Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
• Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

• Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)

Regional Market Summary

• Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2021
• Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
• Figure: 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

 

Chapter 5: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

• Table 5-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

• Figure 5-1: Estimated Number of New Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
• Figure 5-2: Incidence of Cancer by Type, 2020
• Figure 5-3: Distribution of Cancer Incidence by Type, 2020

Market Outlook

• Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2021-2031 ($ millions)

Principal Products

Abecma

APCeden

Breyanzi

CreaVax-RCC

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Tecartus

Yescarta

• Table 5-2: Cell and Gene Therapy in Oncology
• Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

• Table 5-3: Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
• Table 5-4: Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
• Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, January 2022 Data (Phase I through Phase III)

Phase III Development

• Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

• Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020

Market Breakdown of Cell and Gene Therapies

• Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
• Figure 5-7: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

• Table 5-8: Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
• Figure 5-8: Oncology Cell and Gene Therapy Market by General Indication (leukemia, lymphoma, undefined blood cancer, prostate cancer, melanoma, multiple myeloma, other cancers), Estimated 2021 (%)

Regional Market Summary

• Figure 5-9: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2021
• Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
• Figure: 5-10: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

• Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions

Overview

Market Outlook

• Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2021-2031 ($ millions)

Principal Products

Holoclar

Luxturna

• Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions

Trends in Research and Development

• Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
• Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

• Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

• Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

• Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
• Figure 6-2: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

• Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
• Figure: 6-3: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

 

Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

• Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2021-2031 ($ millions)

Principal Products

AlloStem

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

• Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
• Figure 7-2: Musculoskeletal Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

• Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
• Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

• Table 7-4: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022

Market Breakdown of Cell and Gene Therapies

• Table 7-5: Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

• Table 7-6: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
• Figure 7-3: Musculoskeletal Cell and Gene Therapy Market by General Indication (cartilage treatment, bone treatment and other indications), Estimated 2021 (%)

Regional Market Summary

• Figure 7-4: Musculoskeletal Cell and Gene Therapy Approvals by Country/Region, through 2021
• Table 7-7: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
• Figure: 7-5: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

• Table 7-8: Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 8: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

• Figure 8-1: Cell and Gene Therapy Markets in Neurological-Related Conditions, 2021-2031, ($ millions)

Principal Products

Libmeldy

NeuroNata-R

Onpattro

SKYSONA

Stemirac

Zolgensma

• Table 8-1: Cell and Gene Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 8-2: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

• Table 8-3: Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

• Table 8-4: Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
• Figure 8-2: Neurological Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

• Table 8-5: Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
• Figure 8-3: Neurological Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

• Table 8-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 9: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

• Figure 9-1: Cell and Gene Therapy Markets in Other Conditions, 2021-2031, ($ millions)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Oxlumo

Rethymic

Ryplazim

Strimvelis

Temcell/Prochymal/Ryoncil

• Table 9-1: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

• Table 9-2: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
• Figure 9-2: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

• Table 9-3: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
• Figure 9-3: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

 

Chapter 10: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

• Table 10-1: Global Population, through 2050 (population in millions)
• Figure 10-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

• Table 10-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

• Table 10-3: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
• Figure 10-2: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031
• Figure 10-3: Cell and Gene Therapy Market, Distribution of Sales by Product Segment, 2021

Cell vs. Gene Therapy Markets

• Table 10-4: Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
• Figure 10-4: Cell and Gene Therapy Market, Distribution of Sales by Method, 2021

Regional Market Overview

• Table 10-5: Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)

United States

• Table 10-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions)
• Figure 10-5: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
• Table 10-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

• Table 10-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
• Figure 10-6: Europe Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
• Table 10-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

• Table 10-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
• Figure 10-7: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
• Table 10-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

• Table 10-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
• Figure 10-8: Cell and Gene Therapy Market Share Estimates, 2021

 

Chapter 11: Market Participants

Leading Influencers

Advaxis, Inc. (Biosight Therapeutics)

• Table 11-1: Advaxis Corporate Summary

Company Summary

Products

AlloSource

• Table 11-2: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

• Table 11-3: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

• Table 11-4: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

• Table 11-5: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

• Table 11-6: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

• Table 11-7: Atara Biotherapeutics Corporate Summary

Company Summary

Products

Athersys, Inc

• Table 11-8: Athersys Corporate Summary

Company Summary

Products

BioCardia

• Table 11-9: BioCardia Summary

Company Summary

Products

Biogen, Inc.

• Table 11-10: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

• Table 11-11: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

• Table 11-12: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

• Table 11-13: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

• Table 11-14:  Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Caladrius Biosciences

• Table 11-15: Caladrius Biosciences Corporate Summary

Company Summary

Products

Candel Therapeutics

• Table 11-16: Candel Therapeutics Corporate Summary

Company Summary

Products

Castle Creek Biosciences

• Table 11-17:  Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

• Table 11-18: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

• Table 11-19: Cook Myosite Corporate Summary

Company Summary

Products

Cytori Therapeutics, Inc

• Table 11-20: Cytori Therapeutics Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals LLC

• Table 11-21: Dendreon Corporate Summary

Company Summary

Products

FerGene, Inc/Ferring Pharmaceuticals

• Table 11-22:  FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

• Table 11-23: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

• Table 11-24: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

• Table 11-25: Gilead Sciences Corporate Summary

Company Summary

Products

Gradalis, Inc

• Table 11-26: Gradalis Corporate Summary

Company Summary

Products

Helixmith

• Table 11-27:  Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

• Table 11-28: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products

Kiadis Pharma B.V. (Sanofi)

• Table 11-29:  Kiadis Pharma Corporate Summary

Company Summary

Products

Medeor Therapeutics

• Table 11-30: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

• Table 11-31: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

• Table 11-32: MeiraGTxCorporate Summary

Company Summary

Products

Merck & Co., Inc.

• Table 11-33: Merck & Co. Corporate Summary

Company Summary

Products

Mesoblast Ltd.

• Table 11-34: Mesoblast Corporate Summary

Company Summary

Products

Neurotech Pharmaceuticals. Inc.

• Table 11-35: Neurotech Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

• Table 11-36: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

• Table 11-37: Novartis Corporate Summary

Company Summary

Products

NuVasive Biologics

• Table 11-38: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

• Table 11-39: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

• Table 11-40: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

• Table 11-41: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc.( part of Smith & Nephew)

• Table 11-42: Osiris Corporate Summary

Company Summary

Products

Pharmicell

• Table 11-43: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

• Table 11-44: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

• Table 11-45: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

• Table 11-46: Sanofi Corporate Summary

Company Summary

Products

Sotio a.s.

• Table 11-47: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

• Table 11-48: Spark Therapeutics Corporate Summary

Company Summary

Products

Tessa Therapeutics, Ltd.

• Table 11-49: Tessa Therapeutics Corporate Summary

Company Summary

Products

uniQure N.V.

• Table 11-50:  UniQure Corporate Summary

Company Summary

Products

VBL Therapeutics (Vascular Biogenics Ltd.)

• Table 11-51: VBL Therapeutics Corporate Summary

Company Summary

Products

Vericel Corporation

• Table 11-52: Vericel Corporate Summary

Company Summary

Products